Investors Buy Large Volume of DexCom Call Options (NASDAQ:DXCM)

DexCom, Inc. (NASDAQ:DXCM) was the recipient of some unusual options trading activity on Monday. Stock traders acquired 13,720 call options on the company. This represents an increase of 43% compared to the typical daily volume of 9,588 call options.

DexCom Stock Up 4.1 %

Shares of NASDAQ:DXCM traded up $3.04 during trading on Monday, reaching $77.69. The stock had a trading volume of 3,618,705 shares, compared to its average volume of 3,756,195. DexCom has a one year low of $62.34 and a one year high of $142.00. The company has a market capitalization of $30.90 billion, a P/E ratio of 48.16, a PEG ratio of 2.18 and a beta of 1.16. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00. The firm’s 50-day simple moving average is $99.67 and its 200 day simple moving average is $118.01.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. The business had revenue of $1 billion for the quarter, compared to analysts’ expectations of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The company’s revenue was up 15.3% compared to the same quarter last year. During the same period last year, the business earned $0.34 EPS. As a group, research analysts expect that DexCom will post 1.69 EPS for the current fiscal year.

Wall Street Analyst Weigh In

DXCM has been the subject of a number of recent analyst reports. Raymond James upped their price target on shares of DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a report on Friday, April 26th. StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a report on Monday, June 10th. Barclays reduced their price target on DexCom from $138.00 to $113.00 and set an “equal weight” rating on the stock in a report on Monday, July 29th. Robert W. Baird raised their target price on shares of DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a research report on Monday, August 5th. Finally, BTIG Research cut their target price on shares of DexCom from $156.00 to $120.00 and set a “buy” rating on the stock in a research note on Friday, July 26th. Seven analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $111.63.

Insider Buying and Selling at DexCom

In related news, EVP Michael Jon Brown sold 652 shares of the company’s stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $119.24, for a total transaction of $77,744.48. Following the sale, the executive vice president now directly owns 67,560 shares in the company, valued at approximately $8,055,854.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, EVP Michael Jon Brown sold 652 shares of the company’s stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $119.24, for a total transaction of $77,744.48. Following the sale, the executive vice president now owns 67,560 shares of the company’s stock, valued at approximately $8,055,854.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Sadie Stern sold 427 shares of the stock in a transaction on Monday, June 10th. The stock was sold at an average price of $115.05, for a total transaction of $49,126.35. Following the completion of the transaction, the executive vice president now directly owns 75,877 shares in the company, valued at approximately $8,729,648.85. The disclosure for this sale can be found here. Insiders have sold a total of 4,135 shares of company stock worth $446,797 over the last three months. 0.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On DexCom

Large investors have recently added to or reduced their stakes in the stock. Bank of New Hampshire purchased a new stake in shares of DexCom during the first quarter worth $1,508,000. abrdn plc grew its holdings in shares of DexCom by 21.1% during the fourth quarter. abrdn plc now owns 380,535 shares of the medical device company’s stock worth $47,221,000 after buying an additional 66,348 shares in the last quarter. Eagle Asset Management Inc. grew its holdings in shares of DexCom by 21.5% during the fourth quarter. Eagle Asset Management Inc. now owns 1,756,216 shares of the medical device company’s stock worth $217,929,000 after buying an additional 310,728 shares in the last quarter. Alberta Investment Management Corp grew its holdings in shares of DexCom by 27.0% in the fourth quarter. Alberta Investment Management Corp now owns 323,335 shares of the medical device company’s stock valued at $40,123,000 after purchasing an additional 68,723 shares during the period. Finally, Artisan Partners Limited Partnership grew its holdings in shares of DexCom by 164.8% in the fourth quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock valued at $732,169,000 after purchasing an additional 3,672,471 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.